4.3 EFFECT OF LURASIDONE ON BODY WEIGHT AND LABORATORY PARAMETERS IN ADOLESCENT PATIENTS WITH SCHIZOPHRENIA: RESULTS FROM A 6-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
Objectives: To evaluate the effect of short-term treatment with lurasidone on body weight, metabolic parameters, and prolactin levels in adolescent patients with schizophrenia. Methods: In a multicenter, placebo-controlled study, adolescents (13-17 years old) with schizophrenia (DSM-IV-TR criteria)...
Gespeichert in:
Veröffentlicht in: | Journal of the American Academy of Child and Adolescent Psychiatry 2016-10, Vol.55 (10), p.S163-S163 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | S163 |
---|---|
container_issue | 10 |
container_start_page | S163 |
container_title | Journal of the American Academy of Child and Adolescent Psychiatry |
container_volume | 55 |
creator | Goldman, Robert S., PhD Robb, Adelaide S., MD Silva, Robert M., PhD Cucchiaro, Josephine B., PhD Deng, Ling, PhD Loebel, Antony, MD |
description | Objectives: To evaluate the effect of short-term treatment with lurasidone on body weight, metabolic parameters, and prolactin levels in adolescent patients with schizophrenia. Methods: In a multicenter, placebo-controlled study, adolescents (13-17 years old) with schizophrenia (DSM-IV-TR criteria) were randomly assigned to 6 weeks of double-blind treatment with fixed-dose lurasidone 40 mg/d, 80 mg/d, or placebo. Safety analyses included change from baseline to week 6 in body weight (mixed-model repeated-measures analysis) and laboratory parameters (rank analysis ofcovariance [ANCOVA] with the last observation carried forward[LOCF]). Results: A total of 326 patients (mean age=15.4 years) were randomized and received lurasidone 40 mg/d (N=108), 80 mg/d (N=106), or placebo (N=112). Least-squares mean change in weight at week 6 for the lurasidone 40 mg/d, 80 mg/d, and placebo groups was 0.17 kg, 0.49 kg, and 0.05 kg, respectively. Median change at week 6 (LOCF) in total cholesterol (overall) was -4.0 mg/dL, -2.0 mg/dL, and -7.0 mg/dL, respectively; in triglycerides was -2.0 mg/dL, 7.0 mg/dL, and -2.0 mg/dL, respectively; and in glucose was 0.0 mg/dL, 1.0 mg/dL, and 0.0 mg/dL, respectively. Median change in prolactin level at week 6 (LOCF) in male patients was 0.8 ng/mL, 1.0 ng/mL, and 0.0 ng/mL for the lurasidone 40 mg/d, 80 mg/d, and placebo groups, respectively; and in female patients was 0.6 ng/mL, 4.4 ng/mL, and 0.7 ng/mL, respectively. Conclusions: Lurasidone was not associated with clinically meaningful effects on body weight, lipids, glucose, or prolactin in this placebo-controlled trial involving adolescent patients with acute schizophrenia. These findings require confirmation in longer-term studies, they but provide support for the safety of lurasidone as a potential treatment for adolescents with schizophrenia. Longer-term, open-label safety data are currently being collected. |
doi_str_mv | 10.1016/j.jaac.2016.09.198 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1850768271</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0890856716314277</els_id><sourcerecordid>1850768271</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2121-2f1597d1cff197610e10a66152f351fdf45c2e41e374980c31770712bac696963</originalsourceid><addsrcrecordid>eNp9ks-K2zAQxk1poem2L9CToJce1q5G_iO7lIJiKxtTrRVsh5BehKvI4NSb7Fqbwr5Sn7IKKRT2UHQYwfy-YWa-8bz3gAPAkHzaB_uu0wFx_wBnAWTpC28GMaF-HEH60pvhNMN-Gif0tffG2j3GGGiazrzfURAivljwvEVygcS6Zk1ZyIojWaG5LLZow8ubZYtYVSDB5rJmray3aMVqdstbXjeorBArpOBNzqvWJdrSxQZtynaJmnxZfperZc2rkn1GNW_WwuUWtbxFDCX-hvNv16iQ67ng_lyUVXGNVoLlfC79XFZtLYXgBWradbF9673qu9Gad3_jlbde8DZf-kLelDkTviZAwCc9xBndge57yGgC2ADuksQtow9j6Hd9FGtiIjAhjbIU6xAoxRTIj04nmXvhlffxUvd-Oj6cjH1Ud4PVZhy7gzmerII0xjRJCQWHfniG7o-n6eC6c1QEFJMYsKPIhdLT0drJ9Op-Gu666UkBVmf71F6d7VNn-xTOlLPPib5cRMaN-mswk7J6MAdtdsNk9KPaHYf_y78-k-txOAy6G3-aJ2P_taksUVg15_s4nwckIUSE0vAP66in_w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1841702510</pqid></control><display><type>article</type><title>4.3 EFFECT OF LURASIDONE ON BODY WEIGHT AND LABORATORY PARAMETERS IN ADOLESCENT PATIENTS WITH SCHIZOPHRENIA: RESULTS FROM A 6-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY</title><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><source>Access via ScienceDirect (Elsevier)</source><creator>Goldman, Robert S., PhD ; Robb, Adelaide S., MD ; Silva, Robert M., PhD ; Cucchiaro, Josephine B., PhD ; Deng, Ling, PhD ; Loebel, Antony, MD</creator><creatorcontrib>Goldman, Robert S., PhD ; Robb, Adelaide S., MD ; Silva, Robert M., PhD ; Cucchiaro, Josephine B., PhD ; Deng, Ling, PhD ; Loebel, Antony, MD</creatorcontrib><description>Objectives: To evaluate the effect of short-term treatment with lurasidone on body weight, metabolic parameters, and prolactin levels in adolescent patients with schizophrenia. Methods: In a multicenter, placebo-controlled study, adolescents (13-17 years old) with schizophrenia (DSM-IV-TR criteria) were randomly assigned to 6 weeks of double-blind treatment with fixed-dose lurasidone 40 mg/d, 80 mg/d, or placebo. Safety analyses included change from baseline to week 6 in body weight (mixed-model repeated-measures analysis) and laboratory parameters (rank analysis ofcovariance [ANCOVA] with the last observation carried forward[LOCF]). Results: A total of 326 patients (mean age=15.4 years) were randomized and received lurasidone 40 mg/d (N=108), 80 mg/d (N=106), or placebo (N=112). Least-squares mean change in weight at week 6 for the lurasidone 40 mg/d, 80 mg/d, and placebo groups was 0.17 kg, 0.49 kg, and 0.05 kg, respectively. Median change at week 6 (LOCF) in total cholesterol (overall) was -4.0 mg/dL, -2.0 mg/dL, and -7.0 mg/dL, respectively; in triglycerides was -2.0 mg/dL, 7.0 mg/dL, and -2.0 mg/dL, respectively; and in glucose was 0.0 mg/dL, 1.0 mg/dL, and 0.0 mg/dL, respectively. Median change in prolactin level at week 6 (LOCF) in male patients was 0.8 ng/mL, 1.0 ng/mL, and 0.0 ng/mL for the lurasidone 40 mg/d, 80 mg/d, and placebo groups, respectively; and in female patients was 0.6 ng/mL, 4.4 ng/mL, and 0.7 ng/mL, respectively. Conclusions: Lurasidone was not associated with clinically meaningful effects on body weight, lipids, glucose, or prolactin in this placebo-controlled trial involving adolescent patients with acute schizophrenia. These findings require confirmation in longer-term studies, they but provide support for the safety of lurasidone as a potential treatment for adolescents with schizophrenia. Longer-term, open-label safety data are currently being collected.</description><identifier>ISSN: 0890-8567</identifier><identifier>EISSN: 1527-5418</identifier><identifier>DOI: 10.1016/j.jaac.2016.09.198</identifier><identifier>CODEN: JAAPEE</identifier><language>eng</language><publisher>Baltimore: Elsevier Inc</publisher><subject>Adolescents ; Body weight ; Child & adolescent psychiatry ; Cholesterol ; Clinical trials ; Glucose ; Lipids ; Mental disorders ; Parameters ; Patients ; Pediatrics ; Physiological psychology ; Placebo effect ; Prolactin ; Psychiatry ; Psychopharmacology ; Psychotropic drugs ; Safety ; Schizophrenia ; Therapeutic applications ; Triglycerides</subject><ispartof>Journal of the American Academy of Child and Adolescent Psychiatry, 2016-10, Vol.55 (10), p.S163-S163</ispartof><rights>2016</rights><rights>Copyright Lippincott Williams & Wilkins Oct 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jaac.2016.09.198$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,782,786,3552,27931,27932,31006,46002</link.rule.ids></links><search><creatorcontrib>Goldman, Robert S., PhD</creatorcontrib><creatorcontrib>Robb, Adelaide S., MD</creatorcontrib><creatorcontrib>Silva, Robert M., PhD</creatorcontrib><creatorcontrib>Cucchiaro, Josephine B., PhD</creatorcontrib><creatorcontrib>Deng, Ling, PhD</creatorcontrib><creatorcontrib>Loebel, Antony, MD</creatorcontrib><title>4.3 EFFECT OF LURASIDONE ON BODY WEIGHT AND LABORATORY PARAMETERS IN ADOLESCENT PATIENTS WITH SCHIZOPHRENIA: RESULTS FROM A 6-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY</title><title>Journal of the American Academy of Child and Adolescent Psychiatry</title><description>Objectives: To evaluate the effect of short-term treatment with lurasidone on body weight, metabolic parameters, and prolactin levels in adolescent patients with schizophrenia. Methods: In a multicenter, placebo-controlled study, adolescents (13-17 years old) with schizophrenia (DSM-IV-TR criteria) were randomly assigned to 6 weeks of double-blind treatment with fixed-dose lurasidone 40 mg/d, 80 mg/d, or placebo. Safety analyses included change from baseline to week 6 in body weight (mixed-model repeated-measures analysis) and laboratory parameters (rank analysis ofcovariance [ANCOVA] with the last observation carried forward[LOCF]). Results: A total of 326 patients (mean age=15.4 years) were randomized and received lurasidone 40 mg/d (N=108), 80 mg/d (N=106), or placebo (N=112). Least-squares mean change in weight at week 6 for the lurasidone 40 mg/d, 80 mg/d, and placebo groups was 0.17 kg, 0.49 kg, and 0.05 kg, respectively. Median change at week 6 (LOCF) in total cholesterol (overall) was -4.0 mg/dL, -2.0 mg/dL, and -7.0 mg/dL, respectively; in triglycerides was -2.0 mg/dL, 7.0 mg/dL, and -2.0 mg/dL, respectively; and in glucose was 0.0 mg/dL, 1.0 mg/dL, and 0.0 mg/dL, respectively. Median change in prolactin level at week 6 (LOCF) in male patients was 0.8 ng/mL, 1.0 ng/mL, and 0.0 ng/mL for the lurasidone 40 mg/d, 80 mg/d, and placebo groups, respectively; and in female patients was 0.6 ng/mL, 4.4 ng/mL, and 0.7 ng/mL, respectively. Conclusions: Lurasidone was not associated with clinically meaningful effects on body weight, lipids, glucose, or prolactin in this placebo-controlled trial involving adolescent patients with acute schizophrenia. These findings require confirmation in longer-term studies, they but provide support for the safety of lurasidone as a potential treatment for adolescents with schizophrenia. Longer-term, open-label safety data are currently being collected.</description><subject>Adolescents</subject><subject>Body weight</subject><subject>Child & adolescent psychiatry</subject><subject>Cholesterol</subject><subject>Clinical trials</subject><subject>Glucose</subject><subject>Lipids</subject><subject>Mental disorders</subject><subject>Parameters</subject><subject>Patients</subject><subject>Pediatrics</subject><subject>Physiological psychology</subject><subject>Placebo effect</subject><subject>Prolactin</subject><subject>Psychiatry</subject><subject>Psychopharmacology</subject><subject>Psychotropic drugs</subject><subject>Safety</subject><subject>Schizophrenia</subject><subject>Therapeutic applications</subject><subject>Triglycerides</subject><issn>0890-8567</issn><issn>1527-5418</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>7QJ</sourceid><recordid>eNp9ks-K2zAQxk1poem2L9CToJce1q5G_iO7lIJiKxtTrRVsh5BehKvI4NSb7Fqbwr5Sn7IKKRT2UHQYwfy-YWa-8bz3gAPAkHzaB_uu0wFx_wBnAWTpC28GMaF-HEH60pvhNMN-Gif0tffG2j3GGGiazrzfURAivljwvEVygcS6Zk1ZyIojWaG5LLZow8ubZYtYVSDB5rJmray3aMVqdstbXjeorBArpOBNzqvWJdrSxQZtynaJmnxZfperZc2rkn1GNW_WwuUWtbxFDCX-hvNv16iQ67ng_lyUVXGNVoLlfC79XFZtLYXgBWradbF9673qu9Gad3_jlbde8DZf-kLelDkTviZAwCc9xBndge57yGgC2ADuksQtow9j6Hd9FGtiIjAhjbIU6xAoxRTIj04nmXvhlffxUvd-Oj6cjH1Ud4PVZhy7gzmerII0xjRJCQWHfniG7o-n6eC6c1QEFJMYsKPIhdLT0drJ9Op-Gu666UkBVmf71F6d7VNn-xTOlLPPib5cRMaN-mswk7J6MAdtdsNk9KPaHYf_y78-k-txOAy6G3-aJ2P_taksUVg15_s4nwckIUSE0vAP66in_w</recordid><startdate>20161001</startdate><enddate>20161001</enddate><creator>Goldman, Robert S., PhD</creator><creator>Robb, Adelaide S., MD</creator><creator>Silva, Robert M., PhD</creator><creator>Cucchiaro, Josephine B., PhD</creator><creator>Deng, Ling, PhD</creator><creator>Loebel, Antony, MD</creator><general>Elsevier Inc</general><general>Elsevier BV</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QJ</scope><scope>7TK</scope><scope>K9.</scope></search><sort><creationdate>20161001</creationdate><title>4.3 EFFECT OF LURASIDONE ON BODY WEIGHT AND LABORATORY PARAMETERS IN ADOLESCENT PATIENTS WITH SCHIZOPHRENIA: RESULTS FROM A 6-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY</title><author>Goldman, Robert S., PhD ; Robb, Adelaide S., MD ; Silva, Robert M., PhD ; Cucchiaro, Josephine B., PhD ; Deng, Ling, PhD ; Loebel, Antony, MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2121-2f1597d1cff197610e10a66152f351fdf45c2e41e374980c31770712bac696963</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adolescents</topic><topic>Body weight</topic><topic>Child & adolescent psychiatry</topic><topic>Cholesterol</topic><topic>Clinical trials</topic><topic>Glucose</topic><topic>Lipids</topic><topic>Mental disorders</topic><topic>Parameters</topic><topic>Patients</topic><topic>Pediatrics</topic><topic>Physiological psychology</topic><topic>Placebo effect</topic><topic>Prolactin</topic><topic>Psychiatry</topic><topic>Psychopharmacology</topic><topic>Psychotropic drugs</topic><topic>Safety</topic><topic>Schizophrenia</topic><topic>Therapeutic applications</topic><topic>Triglycerides</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Goldman, Robert S., PhD</creatorcontrib><creatorcontrib>Robb, Adelaide S., MD</creatorcontrib><creatorcontrib>Silva, Robert M., PhD</creatorcontrib><creatorcontrib>Cucchiaro, Josephine B., PhD</creatorcontrib><creatorcontrib>Deng, Ling, PhD</creatorcontrib><creatorcontrib>Loebel, Antony, MD</creatorcontrib><collection>CrossRef</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><jtitle>Journal of the American Academy of Child and Adolescent Psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Goldman, Robert S., PhD</au><au>Robb, Adelaide S., MD</au><au>Silva, Robert M., PhD</au><au>Cucchiaro, Josephine B., PhD</au><au>Deng, Ling, PhD</au><au>Loebel, Antony, MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>4.3 EFFECT OF LURASIDONE ON BODY WEIGHT AND LABORATORY PARAMETERS IN ADOLESCENT PATIENTS WITH SCHIZOPHRENIA: RESULTS FROM A 6-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY</atitle><jtitle>Journal of the American Academy of Child and Adolescent Psychiatry</jtitle><date>2016-10-01</date><risdate>2016</risdate><volume>55</volume><issue>10</issue><spage>S163</spage><epage>S163</epage><pages>S163-S163</pages><issn>0890-8567</issn><eissn>1527-5418</eissn><coden>JAAPEE</coden><abstract>Objectives: To evaluate the effect of short-term treatment with lurasidone on body weight, metabolic parameters, and prolactin levels in adolescent patients with schizophrenia. Methods: In a multicenter, placebo-controlled study, adolescents (13-17 years old) with schizophrenia (DSM-IV-TR criteria) were randomly assigned to 6 weeks of double-blind treatment with fixed-dose lurasidone 40 mg/d, 80 mg/d, or placebo. Safety analyses included change from baseline to week 6 in body weight (mixed-model repeated-measures analysis) and laboratory parameters (rank analysis ofcovariance [ANCOVA] with the last observation carried forward[LOCF]). Results: A total of 326 patients (mean age=15.4 years) were randomized and received lurasidone 40 mg/d (N=108), 80 mg/d (N=106), or placebo (N=112). Least-squares mean change in weight at week 6 for the lurasidone 40 mg/d, 80 mg/d, and placebo groups was 0.17 kg, 0.49 kg, and 0.05 kg, respectively. Median change at week 6 (LOCF) in total cholesterol (overall) was -4.0 mg/dL, -2.0 mg/dL, and -7.0 mg/dL, respectively; in triglycerides was -2.0 mg/dL, 7.0 mg/dL, and -2.0 mg/dL, respectively; and in glucose was 0.0 mg/dL, 1.0 mg/dL, and 0.0 mg/dL, respectively. Median change in prolactin level at week 6 (LOCF) in male patients was 0.8 ng/mL, 1.0 ng/mL, and 0.0 ng/mL for the lurasidone 40 mg/d, 80 mg/d, and placebo groups, respectively; and in female patients was 0.6 ng/mL, 4.4 ng/mL, and 0.7 ng/mL, respectively. Conclusions: Lurasidone was not associated with clinically meaningful effects on body weight, lipids, glucose, or prolactin in this placebo-controlled trial involving adolescent patients with acute schizophrenia. These findings require confirmation in longer-term studies, they but provide support for the safety of lurasidone as a potential treatment for adolescents with schizophrenia. Longer-term, open-label safety data are currently being collected.</abstract><cop>Baltimore</cop><pub>Elsevier Inc</pub><doi>10.1016/j.jaac.2016.09.198</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0890-8567 |
ispartof | Journal of the American Academy of Child and Adolescent Psychiatry, 2016-10, Vol.55 (10), p.S163-S163 |
issn | 0890-8567 1527-5418 |
language | eng |
recordid | cdi_proquest_miscellaneous_1850768271 |
source | Applied Social Sciences Index & Abstracts (ASSIA); Access via ScienceDirect (Elsevier) |
subjects | Adolescents Body weight Child & adolescent psychiatry Cholesterol Clinical trials Glucose Lipids Mental disorders Parameters Patients Pediatrics Physiological psychology Placebo effect Prolactin Psychiatry Psychopharmacology Psychotropic drugs Safety Schizophrenia Therapeutic applications Triglycerides |
title | 4.3 EFFECT OF LURASIDONE ON BODY WEIGHT AND LABORATORY PARAMETERS IN ADOLESCENT PATIENTS WITH SCHIZOPHRENIA: RESULTS FROM A 6-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T08%3A23%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=4.3%20EFFECT%20OF%20LURASIDONE%20ON%20BODY%20WEIGHT%20AND%20LABORATORY%20PARAMETERS%20IN%20ADOLESCENT%20PATIENTS%20WITH%20SCHIZOPHRENIA:%20RESULTS%20FROM%20A%206-WEEK,%20DOUBLE-BLIND,%20PLACEBO-CONTROLLED%20STUDY&rft.jtitle=Journal%20of%20the%20American%20Academy%20of%20Child%20and%20Adolescent%20Psychiatry&rft.au=Goldman,%20Robert%20S.,%20PhD&rft.date=2016-10-01&rft.volume=55&rft.issue=10&rft.spage=S163&rft.epage=S163&rft.pages=S163-S163&rft.issn=0890-8567&rft.eissn=1527-5418&rft.coden=JAAPEE&rft_id=info:doi/10.1016/j.jaac.2016.09.198&rft_dat=%3Cproquest_cross%3E1850768271%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1841702510&rft_id=info:pmid/&rft_els_id=1_s2_0_S0890856716314277&rfr_iscdi=true |